Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 145

Results For "liver"

2778 News Found

Alvotech and Teva get US FDA approval of Selarsdi
Drug Approval | April 17, 2024

Alvotech and Teva get US FDA approval of Selarsdi

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva


Cipla Health strengthens its play in beauty and personal care
News | April 16, 2024

Cipla Health strengthens its play in beauty and personal care

CHL is strengthening its play in the fast-growing beauty and personal care sector


Croda and AAHI partner to drive innovation in vaccine development
News | April 15, 2024

Croda and AAHI partner to drive innovation in vaccine development

The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development


USFDA completes inspection of Lupin's Dabhasa facility with no observations
Drug Approval | April 13, 2024

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations


Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
News | April 11, 2024

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility


Pluss unveils Celsure XL VIP pallets
News | April 07, 2024

Pluss unveils Celsure XL VIP pallets

A game changing solution for the pharmaceutical industry


USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
Drug Approval | April 06, 2024

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial


Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Drug Approval | April 06, 2024

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy

Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers


Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
Clinical Trials | April 06, 2024

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial